Acquire the license to the best health content in the world
Contact Us

Predictors Explored for Response to UVB Phototherapy in Psoriasis

Higher body mass index and positive smoking status predict poorer phototherapy response

psoriasis
Adobe Stock

TUESDAY, Oct. 26, 2021 (HealthDay News) -- The Psoriasis Area and Severity Index (PASI) clearance trajectory over the first few weeks of type B ultraviolet (UVB) phototherapy may predict psoriasis clearance, according to a study published in the November issue of the Journal of the European Academy of Dermatology and Venereology.

Nicola Watson, from the Newcastle Hospitals NHS Foundation Trust in the United Kingdom, and colleagues investigated the associations of selected serum biomarkers and the trajectory of response with outcomes of UVB phototherapy. The analysis included 100 patients with psoriasis routinely prescribed narrowband UVB with 18 months of follow-up data.

The researchers found that the median time to relapse was six months if 90 (PASI90) was achieved and four months for <PASI90. Prolonged remission was not seen with PASI100. The median final PASI on UVB completion was 1.0, with 81 percent achieving PASI75 and 41 percent achieving PASI90. There was a significant association observed between improved PASI90 response and lower body mass index, higher baseline PASI, nonsmoking status, and lower cumulative narrowband UVB. There was no association between serum levels of C-reactive protein or vitamin D and either clearance or remission duration. The final outcome was predicted by early treatment response at weeks 2 to 3.

"For the first time, we have shown that PASI clearance trajectory over the first two to three weeks of UVB, can predict psoriasis clearance," the authors write. "This is an important new step towards developing psoriasis personalized prescribing, which can now be formally tested in clinical trials. These simple clinical measures can be used to inform patient treatment expectations, allowing treatment modifications and/or switching to alternative therapies."

Abstract/Full Text (subscription or payment may be required)

Physician's Briefing